GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PharmChem Inc (OTCPK:PCHM) » Definitions » Debt-to-EBITDA

PharmChem (PharmChem) Debt-to-EBITDA : 0.00 (As of Sep. 2023)


View and export this data going back to 2003. Start your Free Trial

What is PharmChem Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

PharmChem's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. PharmChem's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. PharmChem's annualized EBITDA for the quarter that ended in Sep. 2023 was $1.21 Mil. PharmChem's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for PharmChem's Debt-to-EBITDA or its related term are showing as below:

During the past 13 years, the highest Debt-to-EBITDA Ratio of PharmChem was 5.89. The lowest was -1.69. And the median was 1.48.

PCHM's Debt-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.26
* Ranked among companies with meaningful Debt-to-EBITDA only.

PharmChem Debt-to-EBITDA Historical Data

The historical data trend for PharmChem's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmChem Debt-to-EBITDA Chart

PharmChem Annual Data
Trend Dec93 Dec94 Dec95 Dec96 Dec97 Dec98 Dec99 Dec00 Dec01 Dec02
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.09 0.85 0.63 -1.69 4.45

PharmChem Quarterly Data
Jun99 Sep99 Dec99 Mar00 Jun00 Sep00 Dec00 Mar01 Jun01 Sep01 Dec01 Mar02 Jun02 Sep02 Dec02 Mar03 Jun03 Sep03 Sep22 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -53.99 11.86 7.27 - -

Competitive Comparison of PharmChem's Debt-to-EBITDA

For the Medical Devices subindustry, PharmChem's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmChem's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PharmChem's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PharmChem's Debt-to-EBITDA falls into.



PharmChem Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

PharmChem's Debt-to-EBITDA for the fiscal year that ended in Dec. 2002 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.722 + 0.814) / 1.468
=4.45

PharmChem's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


PharmChem  (OTCPK:PCHM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


PharmChem Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PharmChem's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmChem (PharmChem) Business Description

Traded in Other Exchanges
N/A
Address
2411 E. Loop 820 N, Fort Worth, TX, USA, 76118
PharmChem Inc is engaged in selling and distributing of the PharmChek Sweat Patch Device. PharmChek is a system that uses sweat to detect the presence of illegal drugs. It consists of a transparent polyurethane outer covering, a small absorbent pad, and a release liner. Geographically the activities are carried out throughout the United States.
Executives
Alto Investors Palo 10 percent owner 470 UNIVERSITY AVENUE, PALO ALTO CA 94301
Micro Cap Partners Lp 10 percent owner

PharmChem (PharmChem) Headlines

From GuruFocus

PharmChem (PCHM) Announces Response To Opposition

By PRNewswire PRNewswire 08-11-2021